Navigation Links
Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Date:5/19/2008

ability of hydrogen sulfide to induce a state of reversible metabolic hibernation in mice. Ikaria's hydrogen sulfide clinical platform is based on its exclusive, worldwide license from the FHCRC, as well as its own patents.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative pharmaceutical products and drug/device combinations for the critically ill in the hospital and ICU setting. The company's product, INOmax(R) (nitric oxide) for inhalation, is an FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns. The drug also is approved by regulatory authorities and used in Canada, Europe, Australia and Latin America. In addition to the ongoing clinical development as well as the marketing and selling of its INOmax product, Ikaria is engaged in a number of Phase 2 trials with Covox(R) (carbon monoxide) for inhalation and Phase 1 trials with hydrogen sulfide (H2S) for various critical care indications. Ikaria has a staff of approximately 350 people and is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI and manufacturing in Port Allen, LA. For more information on Ikaria, please visit http://www.ikaria.com.

CONTACTS

Matthew Bennett

Ikaria

(908) 238-6673

matthew.bennett@ikaria.com

Jason Rando

The Ruth Group

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
2. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
3. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
4. PacificGMP Completes GMP Product Fill for Trius Therapeutics
5. Cardinal Health Completes Enturia Acquisition
6. DaVita Clinical Research Completes Record Number of Renal Trials in 2007
7. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
8. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
9. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...wswire-FirstCall/ -- Ardea Biosciences, Inc.,(Nasd... "RDEA119, a Potent,and Highly Selective MEK1/2 In...SS) -- induced Chronic Colitis in Mice," was prese...ACG) 2008 Annual Meeting in Orlando,Florida. The ...dy of,RDEA119, the Company,s lead mitogen-activate...
(Date:10/6/2008)... /- Pharmasset, Inc.,(Nasda...., is joining the,Company as Vice President of Inv...Smith will be responsible for all investor relatio...ancial Officer Kurt,Leutzinger., Most recently, D...logy,Analyst at JPMorgan Securities, and has been ...
(Date:10/6/2008)... feature children, parents discussing clinical ...., Oct. 6 /PRNewswire-USNewswire/ -- From asthma a...dren saves lives and improves their,health and wel...es of,Health (NIH), "Children and Clinical Studies...h.gov ), offers parents and health,care providers ...
(Date:10/6/2008)...Oct. 6 /- Genaera,Corporati...econd Phase 1,clinical trial of trodusquemine (MSI...tment of type 2 diabetes and obesity. MSI-1436 is ...target that controls the function,of both the lept...ecrease,appetite. In the study, MSI-1436 was found...
Breaking Medicine Technology:Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4 New discovery leaves blood doping athletes scratching their heads 1667 1 New discovery leaves blood doping athletes scratching their heads 1667 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 1ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 3Genetic variation affects smoking cessation treatment 1663 1Genetic variation affects smoking cessation treatment 1663 2Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment 1661 1Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment 1661 2
...lyses To Be Presented --, SAN FRANCISCO, April 24,...oday announced that data from the Company,s Phase,...ease will be,presented for the first time in the U...s 59th Annual Meeting in Boston on Thursday,May 3... include new,data from both the mild and moderate ...
...., April 24, 2007 /PRNewswire/ -- Accera Inc.,anno...tudy of its,lead compound AC-1202 in Alzheimer,s d...g of the American Academy of Neurology (AAN) in,Bo...ent of the,program, the data will also be featured...ccera,s vice president of clinical development Dr....
Other Medicine Technology:Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 2Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 3Accera, Inc. to Present Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting 2
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...ering potentially fatal liver complications from c...y are given before a stem cell transplant// such a...tment. But chemotherapy causes five to 50 per cent...al complication called veno-occlusive disease (VOD...
... was observed that carbohydrates that originate in...ause arthritis.// Researchers from Harvard Medical...ed GAGs to the defense system in the body that cau...s been a mystery, this new finding may shed light ...
...American Journal of Clinical Nutrition it was obse...preventing the build up of plaque in the arteries ...h has shown antioxidant vitamins can protect again...ries. However, most studies have concentrated on p...
...evels of air pollution can trigger a heart attack ... for more than 24 hours. Researchers say that expo...lutants increased the risk of a heart attack by 40...who are most vulnerable are those already at risk ...
Other Medicine News:
14 cm - 5 1/2, 6.0 mm , for drill handles and hand drills.
Hudson Cranial Drill, complete, consisting of: brace; with extension piece and 4 burs
23 cm - 9, adult size, for skull thickness up to 12 mm.
Length-9 (229 mm) Tapered retractor blades.
Medicine Products: